Eisai Deal History & Licensing Activity
Eisai is a large biotech headquartered in Japan. Over the past three years, Eisai has been involved in 3 licensing and acquisition transactions, with a primary focus on Small Molecules (5 deals). The company currently has 50 active clinical trials, primarily in CNS Disorders.
Deals (12mo)
2
Active Trials
50
Top Modality
Small Molecules
Focus Area
CNS Disorders
Eisai Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Eisai in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| Undisclosed | CORE Biomedicine | Small Molecules | Preclinical | license | Jul 28, 2026 |
| taletrectinib | Eisai Co., Ltd. | Small Molecules | Approved | license | Jan 12, 2026 |
Eisai Pipeline Focus
Therapeutic areas and modalities where Eisai is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Eisai Strategic Signals
Key indicators of Eisai's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Patent Cliffs
- Undisclosed—
- Undisclosed—
Strategic Profile
Acquisition Appetite
Strategic Priorities
Eisai Clinical Pipeline
Eisai has 50 active clinical trials across 6 development phases.
14
Unknown
5
Phase 4
5
Phase 1
1
Phase 1/2
20
Phase 2
5
Phase 3
See How Your Asset Matches Eisai's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for CNS Disorders assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Eisai Licensing & Deal Activity
Eisai is a large biotech company based in Japan that has been actively engaged in licensing transactions across the biopharma landscape. With 3 deals over the past three years, Eisai ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Eisai include CNS Disorders (16 deals and trials), Solid Tumors (15 deals and trials), Oncology (4 deals and trials), and Autoimmune (4 deals and trials). In terms of modality, Eisai has shown particular interest in small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Eisai and 700+ other biopharma companies. Use our Solidus to benchmark your asset against Eisai's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.